IQVIA Holdings Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Ari Bousbib
- Full Time Employees
- 94,000
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 2400 Ellis Road Durham NC United States of America 27703
- IPO Date
- May 9, 2013
- CIK
- 0001478242
- Website
- iqvia.com
- Similar Companies
- Business
- IQVIA Holdings Inc operates as a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences and healthcare industries. The company offers a comprehensive portfolio including clinical trial services; commercial insights; healthcare intelligence; real-world evidence generation; and advanced data analytics powered by IQVIA Connected Intelligence™, Healthcare-grade AI™, and big data resources. Its technology solutions encompass software platforms for orchestrated customer engagement, data management, and commercial orchestration, supported by partnerships with leading technology providers such as NVIDIA and Veeva Systems. IQVIA's service offerings span drug development, regulatory consulting, market access, and patient centricity solutions, targeting pharmaceutical, biotechnology, and medical device companies worldwide. Headquartered in Durham, North Carolina, and founded through the 2016 merger of Quintiles and IMS Health, IQVIA operates in more than 100 countries with approximately 88,000 employees. Recent company developments include a strategic partnership with NVIDIA to integrate generative and agentic AI within clinical research workflows, accelerating innovation and efficiency in drug development. IQVIA also expanded a clinical and commercial collaboration with Veeva Technologies to enhance interoperability and deliver streamlined solutions for customers in clinical development and commercialization. In 2024 and 2025, IQVIA advanced its healthcare data analytics capabilities through acquisitions of healthcare technology firms, reinforcing its technology portfolio and enabling broader service offerings. Additionally, the company continues to support pharmaceutical product launches globally, tracking and analyzing launch excellence to optimize commercial success across multiple therapeutic areas. IQVIA's ongoing investments in AI and integrated technology ecosystems position it at the forefront of healthcare intelligence and life sciences services innovation.
Company News
Contrasting IQVIA (NYSE:IQV) and Bullfrog AI (NASDAQ:BFRG)
IQVIA Stock Rises 60% in 6 Months: Here's What You Should Know
Why IQVIA Holdings (IQV) is a Top Momentum Stock for the Long-Term
Arizona State Retirement System Buys 2,372 Shares of IQVIA Holdings Inc. $IQV
IQVIA Announces Pricing of Senior Notes
IQVIA Announces Offering of Senior Notes
IQVIA Announces Offering of Senior Notes
B. Metzler seel. Sohn & Co. AG Lowers Holdings in IQVIA Holdings Inc. $IQV
IQVIA's Predictive Clinical Development Provides Sponsors With Significant Efficiencies to Get Treatments to Market Faster
IQVIA Wins Multiple Industry Awards for AI and Technology Innovation Across Life Sciences and Healthcare
Why Is IQVIA (IQV) Up 5.6% Since Last Earnings Report?
Here's Why You Should Retain IQVIA Stock in Your Portfolio Now
Callan Family Office LLC Invests $1.75 Million in IQVIA Holdings Inc. $IQV
IQVIA (NYSE:IQV) versus BioLife Solutions (NASDAQ:BLFS) Head to Head Review
IQVIA's AI-Enabled Clinical Decision Support Tool Wins 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year
BlackRock Inc. Takes Position in IQVIA Holdings Inc. $IQV
Bruni J V & Co. Co. Purchases New Shares in IQVIA Holdings Inc. $IQV
IQVIA Ranked No. 1 Pharmaceutical Technology Provider by Everest Group
IQV Stock Gains 42% in 3 Months: Here's What You Should Know
Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term